María Dolores Caballero Barrigón-rekin lankidetzan egindako argitalpenak (8)

2010

  1. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia

    Annals of Hematology, Vol. 89, Núm. 11, pp. 1073-1080

2002

  1. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome

    Blood, Vol. 99, Núm. 5, pp. 1853-1856

2000

  1. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

    Hematology Journal, Vol. 1, Núm. 1, pp. 28-36

  2. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: A comparative study of efficacy and toxicity from the Spanish Registry for transplantation in multiple myeloma

    British Journal of Haematology, Vol. 109, Núm. 1, pp. 138-147

1998

  1. Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry

    Bone Marrow Transplantation, Vol. 21, Núm. 2, pp. 133-140

1997

  1. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

    Blood, Vol. 90, Núm. 6, pp. 2465-2470

1994

  1. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the spanish cooperative group GEL/TAMO

    Bone Marrow Transplantation, Vol. 14, Núm. 2, pp. 279-286

1993

  1. Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: A report from the Spanish GEL/TAMO Cooperative Group

    Annals of Hematology, Vol. 67, Núm. 3, pp. 111-114